Plain-English translation of NCT07307235 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Type 2 Diabetes research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether iGlarLixi, a new injectable medication that combines two diabetes drugs in one injection, works better than standard insulin therapy for people whose type 2 diabetes is not well controlled by pills alone. About 1,316 adults in China will be randomly assigned to receive either iGlarLixi or standard insulin injections, along with their current oral diabetes medications. The study will compare how well each treatment lowers blood sugar and how safe they are.
Many people with type 2 diabetes find that oral medications alone are not enough to bring their blood sugar to healthy levels, and they need to start insulin injections. This medication may offer a simpler option — one injection instead of multiple medications — while also helping control blood sugar more effectively.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the new medication or standard insulin therapy, both given as injections under the skin. You'll continue taking your current oral diabetes pills, which your doctor may adjust as needed. You'll visit the research center regularly so doctors can check your blood sugar levels, monitor how well the treatment is working, and watch for any side effects. The study takes place across about 40 medical centers in China.
AI-generated summary from trial data · Jul 19, 2026 · Not medical advice
China